APA (7th ed.) Citation

P, C., C, J., E, S., L, S., P, K., C, d. L., . . . MD, S. (2020). First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 70(10), 2073. https://doi.org/10.1093/cid/ciz653

Chicago Style (17th ed.) Citation

P, Cicconi, et al. "First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 70, no. 10 (2020): 2073. https://doi.org/10.1093/cid/ciz653.

MLA (9th ed.) Citation

P, Cicconi, et al. "First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 70, no. 10, 2020, p. 2073, https://doi.org/10.1093/cid/ciz653.